Literature DB >> 25817464

Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434.

Jana Pastuschek1, Jenny Poetzsch2, Diana M Morales-Prieto1, Ekkehard Schleußner1, Udo R Markert3, Georgi Georgiev4.   

Abstract

The development of the follicle and competent oocyte is highly coordinated, requiring interplay among several systems. These implicate endocrine, immune, and metabolic signals, intrafollicular paracrine factors from theca, mural, and cumulus granulosa cells, and the oocyte itself. Granulosa cells play a key role in their interaction. COV434 is one of the few human granulosa cell lines that can be used as an in vitro model for ovarian research. We aimed to evaluate the possible activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway by IL-6-type cytokines leukemia inhibitory factor (LIF) and oncostatin M (OSM) in COV434 cells. Expression of GP130 (glycoprotein 130), STAT3 (signal transducer and activators of transcription 3), PIAS3 (protein inhibitor of activated STAT 3), and SOCS3 (suppressor of cytokine signaling 3) genes after stimulation with LIF or OSM was assessed using RT-qPCR (real-time PCR). GP130 transcripts were significantly upregulated after incubation with LIF or OSM for 24h. Expression of the STAT3 gene was stimulated only after incubation with LIF, but not OSM. SOCS3 showed significant upregulation for all time periods and the levels of PIAS3 were initially down- and after 24h upregulated. Furthermore, the major signaling components of the JAK/STAT pathway, GP130 and STAT3, and the kinase activation patterns of STAT3, were examined at protein level. We found constitutive protein expression for GP130, STAT3, pSTAT3(ser727) and upregulation of pSTAT3(tyr705) by LIF and OSM. Our results demonstrate the activation of the JAK/STAT pathway by LIF and OSM in human granulosa cells.
Copyright © 2015. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  COV434 cell line; Granulosa cells; IL6-type cytokines; JAK/STAT pathway; LIF; OSM

Mesh:

Substances:

Year:  2015        PMID: 25817464     DOI: 10.1016/j.jri.2015.03.002

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  6 in total

1.  Jumonji Domain-containing Protein-3 (JMJD3/Kdm6b) Is Critical for Normal Ovarian Function and Female Fertility.

Authors:  Sambit Roy; Niharika Sinha; Binbin Huang; Holly Cline-Fedewa; Norbert Gleicher; Jianrong Wang; Aritro Sen
Journal:  Endocrinology       Date:  2022-05-01       Impact factor: 5.051

2.  F4/80+ Kupffer Cell-Derived Oncostatin M Sustains the Progression Phase of Liver Regeneration through Inhibition of TGF-β2 Pathway.

Authors:  Qingjun Lu; Hao Shen; Han Yu; Jing Fu; Hui Dong; Yao Chen; Hongyang Wang
Journal:  Molecules       Date:  2021-04-13       Impact factor: 4.411

3.  Rescue IVM of Denuded GV- and MI-Stage Oocytes of Premenopausal Rats with Oncostatin M, Insulin-like Growth Factor I, and Growth Hormone.

Authors:  Yesim Akdemir; Yaprak Donmez Cakil; Belgin Selam; Mustafa Erinc Sitar; Mehmet Cincik
Journal:  Life (Basel)       Date:  2022-08-16

Review 4.  Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies.

Authors:  Roseanne Rosario; Wanyuan Cui; Richard A Anderson
Journal:  Reprod Fertil       Date:  2022-07-11

5.  Signal transducer and activator of transcription (STAT) 1 and STAT3 are expressed in the human ovary and have Janus kinase 1-independent functions in the COV434 human granulosa cell line.

Authors:  E R Frost; E A Ford; A E Peters; N L Reed; E A McLaughlin; M A Baker; R Lovell-Badge; J M Sutherland
Journal:  Reprod Fertil Dev       Date:  2020-08       Impact factor: 2.311

6.  OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition.

Authors:  Hunter Covert; Liliana F Mellor; Cody L Wolf; Nicole Ankenbrandt; Jacqueline M Emathinger; Ken Tawara; Julie Thom Oxford; Cheryl L Jorcyk
Journal:  Cancer Manag Res       Date:  2019-08-15       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.